Polio endgame: The global introduction of inactivated polio vaccine

Expert Review of Vaccines

Volumn 14, Issue 5, 2015, Pages 749-762

  Patel, Manish ^a   Zipursky, Simona ^b   Orenstein, Walt ^c   Garon, Julie ^c   Zaffran, Michel ^b  

^a Task Force for Global Health   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c EMORY UNIVERSITY   (United States)

Author keywords

Poliomyelitis

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION RISK; POLIOMYELITIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; WORLD HEALTH ORGANIZATION; DISEASE ERADICATION; DISEASE TRANSMISSION; HEALTH; HEALTH CARE POLICY; IMMUNOLOGY; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; VACCINATION;

DISEASE ERADICATION; DISEASE TRANSMISSION, INFECTIOUS; GLOBAL HEALTH; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84927782291     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1001750     Document Type: Review

References (69)

1. Available from: www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx [Last accessed 5 January 2014]
2. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. Economic analysis of the global polio eradication initiative. Vaccine 2010;29(2):334-43
3. Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th edition. Elsevier, Philadelphia, PA, USA; 2013. p. 598-645
4. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012;11(4): 449-59
5. Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33(4):680-702
6. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59: 587-635
7. Vidor E, Plotkin SA. Poliovirus vaccine-inactivated. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccine. 6th edition. Elsevier; Philadelphia: 2013. p. 573-97
8. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8(4):e1002599
9. Herremans MM, van Loon AM, Reimerink JH, et al. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. Clin Diagn Lab Immunol 1997;4(5):499-503
10. Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science 2014; 345(6199):922-5 . This study demonstrated in a real-world settting with high force of transmission that parenteral administration of inactivated polio vaccine (IPV) can significantly reduce fecal shedding of polioviruses in infants and children with prior exposure to oral polio vaccine (OPV), thus providing support to the contention that IPV vaccination may curtail transmission in a outbreak scenario post-eradication
11. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991;163(1):1-6
12. Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018. WHO/POLIO/13.02. 2013. Available from: www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP-EN-US.pdf [Last accessed 22 July 2014]
13. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012-conclusions and recommendations. Wkly Epidemiol Rec 2012;87(21):201-16
14. WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012-conclusions and recommendations. Wkly Epidemiol Rec 2013;88(1):1-16
15. WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2013-conclusions and recommendations. Wkly Epidemiol Rec 2013;88(20):201-6
16. WHO Department of Immunization, Vaccines and Biologicals. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010;85(23):213-28
17. WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2013-conclusions and recommendations. Wkly Epidemiol Rec 2014;89(1):1-20
18. Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006;26(6):1471-505
19. Cochi SL, Freeman A, Guirguis S, et al. Global polio eradication initiative: lessons learned and legacy. J Infect Dis 2014; 210(Suppl 1):S540-6
20. Platt LR, Estivariz CF, Sutter RW. Vaccine-Associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014; 210(Suppl 1):S380-9
21. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-Associated disease. Clin Infect Dis 1992;14(2):568-79
22. Available from: www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx [Last accessed 15 January 2014]
23. World Health Organization. 7th Meeting of the SAGE Polio Working Group, WHO, Geneva, 7-8 October 2013. Available from: www.who.int/immunization/sage/meetings/2013/november/3-SAGE-Note-for-the-Record-exec-summary.pdf [Last accessed 26 June 2014]
24. WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on immunization, October 2014-conclusions and recommendations. Wkly Epidemiol Rec 2014;89(50):561-76
25. World Health Organization. Cessation of routine oral polio vaccine (OPV) use after global polio eradication. Framework for national policy makers in OPV-using countries (WHO/POLIO/05.02). World Health Organization Geneva, Switzerland; 2005
26. Mas Lago P, Caceres VM, Galindo MA, et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol 2001;30(5): 1029-34
27. Deshpande JM, Nadkarni SS, Siddiqui ZA. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. Indian J Med Res 2003;118:217-23 . This paper reports a poliovirus outbreak from a laboratory reference strain of the type 2 virus several years after the interuption of transmission of this virus in India. The paper highlights the need for immunity against polioviruses after interruption of poliovirus transmission.
28. Diop OM, Burns CC, Wassilak SG, Kew OM; Centers for Disease Control and Prevention (CDC). Prevention. Update on vaccine-derived polioviruses-worldwide, July 2012-December 2013. MMWR Morb Mortal Wkly Rep 2014;63(11):242-8
29. Robertson S. Poliomyelitis. In: WHO, editor. Immunological basis for immunization. World Health Organization; Geneva: 1993. p. 1-24. Available from: http://www.who.int/ihr/polio1993en.pdf [Last accessed 5 January 2015]
30. Estivariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013;3(3):309-15
31. Grassly NC. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-Analysis. J Infect Dis 2014;210(Suppl 1):S439-46 . This paper reviews the immune response of one and two doses of IPV and demonstrates that seroconversion to IPV improves with increasing age at administration during the first 20 weeks of life likely due to lesser interference from decay in maternally derived circulating antibodies.
32. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368(5):416-24 . This study provides scientific evidence of an improved immune response from a single dose of IPV when administered at 4 months of age compared with historical studies where IPV was administered at younger ages. One dose also has a priming effect in nearly all children, whereby these children mounted antibody response within 7 days of a subsequent exposure to IPV. While promsing, whether priming equates to protection against clinical disease remains unknown.
33. Sutter RW, Pallansch MA, Sawyer LA, et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995;754:289-99
34. Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988;1(8591):897-9 . This is a study demonstrating that a single dose of IPV provides protection against clinical disease in a real-world African setting.
35. Kapusinszky B, Molnar Z, Szomor KN, Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccine-Associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol 2010; 58(2):211-17
36. World Health Organization. Scientific evidence in support of: 5th Meeting of the SAGE Working Group, WHO, Geneva, September 3-4, 2012. Available from: www.who.int/immunization/sage/meetings/2012/november/3-SAGE-WG-Scientific-Evidence22Oct2012.pdf [Last accessed 26 June 2014]
37. Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev Infect Dis 1984; 6(Suppl 2):S413-18
38. Estivariz CF, Molnar Z, Venczel L, et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 2011;174(3): 316-25
39. Kohler KA, Banerjee K, Gary Hlady W, et al. Vaccine-Associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002;80(3):210-16
40. John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet 2014;384(9953): 1505-12 . This study demonstrated that a single dose of IPV boosted intestinal immunity in children younger than 5 years who had prior exposure to OPV highlighting that IPV use in children with prior OPV exposure may contribute to interruption of transmission in the setting of an outbreak post-eradication.
41. Cuba IPVSCG. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007;356(15):1536-44
42. World Health Organization unpublished data, presented at SAGE. Available from: www.who.int/immunization/sage/meetings/2012/november/3-SAGE-WG-Scientific-Evidence22Oct2012.pdf
43. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014;210(Suppl 1):S485-97
44. Moriniere BJ, van Loon FP, Rhodes PH, et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993;341(8860):1545-50
45. Estivariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012;12(2):128-35 . This study demonstrated that inactivated polio vaccine closes the immunity gap to types 2 and 3 poliovirus in children who remained seronegative after multiple prior doses of trivalent OPV.
46. Available from: www.who.int/immunization/diseases/poliomyelitis/inactivated-polio-vaccine/en/[Last accessed 15 January 2014]
47. Mahmood K, Pelkowski S, Atherly D, et al. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother 2013; 9(9):1894-902
48. WHO Department of Immunization, Vaccines and Biologicals. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2014-conclusions and recommendations. Wkly Epidemiol Rec 2014;89(21):221-36
49. Available from: www.unicef.org/supply/index-66260.html [Last accessed 15 January 2014]
50. Available from: www.who.int/immunization/diseases/poliomyelitis/inactivated-polio-vaccine/MDVP-Nov2014.pdf?ua=1 [Last accessed 21 November 2014]
51. World Health Organization. Expanded Program on Immunization: WHO Policy Statement: Multi-dose Vial Policy (MDVP). Available from: http://apps.who.int/iris/bitstream/10665/135972/1/WHO-IVB-14.07-eng.pdf [Last accessed 5 January 2015]
52. Available from: www.gavialliance.org/support/nvs/inactivated-polio-vaccine/[Last accessed 15 January 2014]
53. World Health Organization. Principles and considerations for adding a vaccine to a national immunization programme, 2014. Available from: www.who.int/immunization/programmes-systems/policies-strategies/vaccine-intro-resources/nvi-guidelines/en/[Last accessed 26 June 2014]
54. Available from: www.unicef.org/supply/files/Product-Menu-March-2014.pdf [Last accessed 15 January 2014]
55. World Health Organization. Temperature sensitivity of vaccines (WHO/IVB/06.10). World Health Organization Geneva, Switzerland; 2006
56. World Health Organization. Preventing freeze damage to vaccines. Available from: whqlibdoc.who.int/hq/2007/WHO-IVB-07.09-eng.pdf [Last accessed 26 June 2014]
57. Wallace AS, Mantel C, Mayers G, et al. Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine 2014;32(41):5301-10
58. Available from: www.who.int/immunization/global-vaccine-Action-plan/SAGE-DoV-GVAP-Assessment-report-2014-English. pdf?ua=1 [Last accessed 21 November 2014]
59. Hickling J, Jones R, Nundy N. Improving the Affordability of Inactivated Poliovirus Vaccine (IPV) for use in Low-And Middle-Income Countries. 2012.Available from: www.path.org/publications/detail.php? i=1809 [Last accessed 9 December 2013]
60. Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis 2012;16(2): e110-16
61. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362(25):2351-9
62. Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012;205(2):237-43
63. Verdijk P, Rots NY, van Oijen MG, et al. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine 2013;31(47):5531-6
64. Shirato H, Someya Y, Ochiai M, et al. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014;32(40):5163-9
65. Available from: http://ibb.gatech.edu/hg-news/72457 [Last accessed 26 June 2014]
66. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009;333: 369-93
67. World Health Organization. Sixty-seventh World Health Assembly: poliomyelitis: intensification of the global eradication initiative. Available from: http://apps.who. int/gb/ebwha/pdf-files/WHA67/A67-38-en. pdf [Last accessed 11 September 2014]
68. Available from: www.polioeradication.org/Portals/0/Wild-poliovirus-list-2009-2014-09DEC.pdf
69. Available from: www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx